Veradermics announces launch of public offering
Seeking Alpha News (Mon, 27-Apr 5:48 PM ET)
Veradermics Announces Launch of Public Offering
Business Wire (Mon, 27-Apr 5:26 PM ET)
Buy Rating Reiterated as Strong VDPHL01 Data De-Risk Program and Drive Price Target Increase to $120
TipRanks (Mon, 27-Apr 2:45 PM ET)
Market Chameleon (Mon, 27-Apr 6:29 AM ET)
Veradermics Reports Positive Phase 2/3 Data for VDPHL01
TipRanks (Mon, 27-Apr 9:32 AM ET)
Market Chameleon (Mon, 27-Apr 3:51 AM ET)
Business Wire (Mon, 27-Apr 7:00 AM ET)
Business Wire (Sun, 26-Apr 4:00 PM ET)
Business Wire (Mon, 30-Mar 7:30 AM ET)
Business Wire (Wed, 18-Mar 7:00 AM ET)
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Veradermics trades on the NYSE stock market under the symbol MANE.
As of April 29, 2026, MANE stock price climbed to $106.55 with 598,765 million shares trading.
MANE has a market cap of $3.74 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that MANE belongs to (by Net Assets): VTI, VXF, SCHA, LFSC, ITOT.
MANE support price is $95.71 and resistance is $110.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MANE shares will trade within this expected range on the day.
